Impact of baseline characteristics on the efficacy of once-weekly subcutaneous semaglutide among participants with type 2 diabetes: A post hoc analysis of SUSTAIN China.

Ji L, Lu Y, Shen Z, Hu P, Liu W, Zhang Q, Shi B

Diabetes, obesity & metabolism16 Sept 2024Cited by 2 (Europe PMC)

PMID39279647DOI10.1111/dom.15888PepBankPUB-39279647

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, the HbA1c efficacy of semaglutide versus sitagliptin was not significantly affected by most baseline characteristics studied.
In plain wordsIn adults with type 2 diabetes, how well semaglutide lowered HbA1c compared with sitagliptin did not depend on most starting characteristics.
Peptide
Semaglutide
Outcome
No significant changeHbA1c change by baseline characteristics
Study
n = 868
Comparator
Sitagliptin 100 mg
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.5 and 1.0 mg once weekly · subcutaneousAs given in this study (human).
Source sentences
Summary
In both populations the efficacy of once-weekly subcutaneous semaglutide 0.5 and 1.0 mg versus sitagliptin was not significantly affected by most of the baseline characteristics studied.
3 context sentences(design, population, supporting numbers)
Summary · context
Changes from baseline to end of treatment (EOT) in glycated haemoglobin (HbA1c) and body weight
Summary · context
To investigate the impact of baseline characteristics on the efficacy of once-weekly subcutaneous semaglutide 0.5 and 1.0 mg in participants with type 2 diabetes (T2D) from the SUSTAIN China trial.
Summary · context
In this post hoc analysis, data for semaglutide 0.5 and 1.0 mg versus sitagliptin 100 mg were analysed in the total (n = 868) and Chinese-only (n = 605) populations.
Report a problemFND-3927964701
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, the body weight efficacy of semaglutide versus sitagliptin was not significantly affected by most baseline characteristics studied.
In plain wordsIn adults with type 2 diabetes, how well semaglutide cut body weight compared with sitagliptin did not depend on most starting characteristics.
Peptide
Semaglutide
Outcome
No significant changeBody weight change by baseline characteristics
Study
n = 868
Comparator
Sitagliptin 100 mg
Outcome group
Body weight · Metabolic and weight
Studied dose
0.5 and 1.0 mg once weekly · subcutaneousAs given in this study (human).
Source sentences
Summary
In both populations the efficacy of once-weekly subcutaneous semaglutide 0.5 and 1.0 mg versus sitagliptin was not significantly affected by most of the baseline characteristics studied.
3 context sentences(design, population, supporting numbers)
Summary · context
Changes from baseline to end of treatment (EOT) in glycated haemoglobin (HbA1c) and body weight
Summary · context
To investigate the impact of baseline characteristics on the efficacy of once-weekly subcutaneous semaglutide 0.5 and 1.0 mg in participants with type 2 diabetes (T2D) from the SUSTAIN China trial.
Summary · context
In this post hoc analysis, data for semaglutide 0.5 and 1.0 mg versus sitagliptin 100 mg were analysed in the total (n = 868) and Chinese-only (n = 605) populations.
Report a problemFND-3927964702
03HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, the proportion reaching HbA1c below 7% with semaglutide was not affected by baseline HbA1c.
In plain wordsIn adults with type 2 diabetes, the share reaching the HbA1c target on semaglutide did not depend on starting HbA1c.
Peptide
Semaglutide
Outcome
No significant changeProportion reaching HbA1c <7% by baseline HbA1c
Study
n = 868
Comparator
Sitagliptin 100 mg
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.5 and 1.0 mg once weekly · subcutaneousAs given in this study (human).
Source sentences
Summary
The proportion of participants achieving the target HbA1c interaction > 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate the impact of baseline characteristics on the efficacy of once-weekly subcutaneous semaglutide 0.5 and 1.0 mg in participants with type 2 diabetes (T2D) from the SUSTAIN China trial.
Summary · context
In this post hoc analysis, data for semaglutide 0.5 and 1.0 mg versus sitagliptin 100 mg were analysed in the total (n = 868) and Chinese-only (n = 605) populations.
Report a problemFND-3927964703
04HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, self-monitored plasma glucose fluctuation indicated less glucose variability with semaglutide than with sitagliptin.
In plain wordsIn adults with type 2 diabetes, blood sugar varied less during the day with semaglutide than with sitagliptin.
Peptide
Semaglutide
Outcome
DecreaseGlucose variability (SMPG fluctuation)
Study
n = 868
Comparator
Sitagliptin 100 mg
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.5 and 1.0 mg once weekly · subcutaneousAs given in this study (human).
Source sentences
Summary
SMPG fluctuation and dTIR indicated less glucose variability in participants treated with semaglutide 0.5 and 1.0 mg versus sitagliptin
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate the impact of baseline characteristics on the efficacy of once-weekly subcutaneous semaglutide 0.5 and 1.0 mg in participants with type 2 diabetes (T2D) from the SUSTAIN China trial.
Summary · context
In this post hoc analysis, data for semaglutide 0.5 and 1.0 mg versus sitagliptin 100 mg were analysed in the total (n = 868) and Chinese-only (n = 605) populations.
Report a problemFND-3927964704
05HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, derived time-in-range indicated less glucose variability with semaglutide than with sitagliptin.
In plain wordsIn adults with type 2 diabetes, a time-in-range measure showed less blood sugar variation with semaglutide than with sitagliptin.
Peptide
Semaglutide
Outcome
Direction not reportedDerived time-in-range (dTIR) of seven-point SMPG
Study
n = 868
Comparator
Sitagliptin 100 mg
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.5 and 1.0 mg once weekly · subcutaneousAs given in this study (human).
Source sentences
Summary
SMPG fluctuation and dTIR indicated less glucose variability in participants treated with semaglutide 0.5 and 1.0 mg versus sitagliptin
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate the impact of baseline characteristics on the efficacy of once-weekly subcutaneous semaglutide 0.5 and 1.0 mg in participants with type 2 diabetes (T2D) from the SUSTAIN China trial.
Summary · context
In this post hoc analysis, data for semaglutide 0.5 and 1.0 mg versus sitagliptin 100 mg were analysed in the total (n = 868) and Chinese-only (n = 605) populations.
Report a problemFND-3927964705
06HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, HOMA-beta ratios to baseline at end of treatment were greater with semaglutide than with sitagliptin.
In plain wordsIn adults with type 2 diabetes, a measure of insulin-producing cell function rose more with semaglutide than with sitagliptin.
Peptide
Semaglutide
Outcome
IncreaseHOMA-beta ratio to baseline at end of treatment
Study
n = 868
Comparator
Sitagliptin 100 mg
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.5 and 1.0 mg once weekly · subcutaneousAs given in this study (human).
Source sentences
Summary
and the HOMA-β ratios to baseline at EOT were greater with semaglutide 0.5 and 1.0 mg versus sitagliptin (p < 0.05)
2 context sentences(design, population, supporting numbers)
Summary · context
To investigate the impact of baseline characteristics on the efficacy of once-weekly subcutaneous semaglutide 0.5 and 1.0 mg in participants with type 2 diabetes (T2D) from the SUSTAIN China trial.
Summary · context
In this post hoc analysis, data for semaglutide 0.5 and 1.0 mg versus sitagliptin 100 mg were analysed in the total (n = 868) and Chinese-only (n = 605) populations.
Report a problemFND-3927964706

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Impact of baseline characteristics on the efficacy of once-weekly subcutaneous semaglutide among participants with type 2 diabetes: A post hoc analysis of SUSTAIN China.

Summary

Results from this study6

Version history

Subjects

Publication types

MeSH terms

Keywords